Contract facts
FederalEXERCISE OPTION YEAR 4 - BPA 36E79722A0025 is a federal award for Nac Pharmaceuticals (36E797) held by Telix Pharmaceuticals (Us) Inc. Estimated value —. Related solicitation VA-797P-12-Q-0002.
EXERCISE OPTION YEAR 4 - BPA 36E79722A0025
Incumbent footprint
Public recordTelix Pharmaceuticals (Us) Inc — $6.9M obligated across 17 awards (firm-wide, all agencies).
Related awards
Same incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 36E79722A0025?
36E79722A0025 (Exercise OPTION YEAR 4 - BPA 36e79722a0025) is a Nac Pharmaceuticals (36E797) award with an estimated value of —, currently held by Telix Pharmaceuticals (Us) Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is 36E797-22-A-0025?
36E797-22-A-0025 is the dashed form of PIID 36E79722A0025 (Exercise OPTION YEAR 4 - BPA 36e79722a0025), held by Telix Pharmaceuticals (Us) Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded 36E79722A0025?
Nac Pharmaceuticals (36E797) awarded 36E79722A0025 to Telix Pharmaceuticals (Us) Inc.
Who is the incumbent on 36E79722A0025?
Telix Pharmaceuticals (Us) Inc is the incumbent with $6.9M across 17 related awards in SCOUT’s public footprint.
When does Telix Pharmaceuticals (Us) Inc’s 36E79722A0025 come up for recompete?
SCOUT tracks a period-of-performance end of an unstated date. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.